On September 21, 2026, Bradlin Ventures Ltd. entered into an amalgamation agreement with Celexir Inc., pursuant to which Brandlin and Celexir will effect a business combination that will result in Brandlin indirectly acquiring all of the business and operations of Celexir.
Upon closing of the proposed transaction, Brandlin anticipates changing its name to Celexir Inc., and listing on the Canadian Securities Exchange.
As a condition to completing the acquisition, the parties intend to complete a non-brokered private placement financing of subscription receipts to raise minimum gross proceeds of $2,000,000, through the issuance of a minimum of 4,000,000 subscription receipts at a price of $0.50 per subscription receipt.
Cassels is acting for Bradlin Ventures.